REG - Fusion Antibodies - Exercise of share options and total voting rights

Fusion AntibodiesAnnouncement

14/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211214:nRSN4932Va&default-theme=true

RNS Number : 4932V  Fusion Antibodies PLC  14 December 2021

14 December 2021

 

Fusion Antibodies plc

("Fusion" or the "Company")

 

Exercise of share options and total voting rights

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and diagnostic
applications, announces an exercise of share options in the Company ("Ordinary
Shares") by Richard Buick, Chief Scientific Officer of the Company.

On 13 December 2021, Richard Buick exercised 20,000 share options. These share
options were granted pursuant to the Company's EMI Employee Share Option
Scheme with an exercise price of 54.5 pence per share.  The new Ordinary
Shares issued pursuant to this exercise will be admitted to trading on AIM
pursuant to the Block Admission announced by the Company on 27 September 2021.
The notification below, made in accordance with the requirements of the UK
Market Abuse Regulation, provides further detail.

 

Following the above exercise of 20,000 share options, Richard Buick holds
631,250 Ordinary Shares, representing approximately 2.43 per cent. of the
Company's enlarged issued share capital.

Following the exercise of share options, the total number of Ordinary Shares
in issue is now 25,938,280. The Company does not currently hold any Ordinary
Shares in treasury. Therefore, the total number of voting rights in the
Company is 25,938,280, which may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in the Company under
the FCA's Disclosure Guidance and Transparency Rules.

The following notification, made in accordance with the requirements of the UK
Market Abuse Regulation, gives further details.

 1     Details of the person discharging managerial responsibilities / person closely
       associated
 a)    Name                                                           Richard Buick
 2     Reason for the notification
 a)    Position/status                                                Director - Chief Scientific Officer
 b)    Initial notification /Amendment                                Initial notification
 3     Details of the issuer, emission allowance market participant, auction
       platform, auctioneer or auction monitor
 a)    Name                                                           Fusion Antibodies plc
 b)    LEI                                                            213800KBAYRC9VOQ9V39
 4     Details of the transaction(s): section to be repeated for (i) each type of

     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
       place where transactions have been conducted
 a)    Description of the financial instrument, type of instrument    Ordinary shares of 4p each in Fusion Antibodies plc

       Identification code                                            Identification code (ISIN) for Fusion Antibodies plc ordinary shares:
                                                                      GB00BDQZGK16
 b)    Nature of the transaction                                      Exercise of share options

 c)    Price(s) and volume(s)                                          Price(s)   Volume(s)
                                                                      £0.545      20,000

 
 d)    Aggregated information
       - Aggregated volume                                            20,000

       - Price                                                        £0.545

 e)    Date of the transaction                                        13 December 2021

 f)    Place of the transaction                                       Outside a trading venue

 

d)

Aggregated information

 

 

- Aggregated volume

 

20,000

 

- Price

 

£0.545

 

e)

Date of the transaction

13 December 2021

 

f)

Place of the transaction

Outside a trading venue

 

Enquiries:

 

 Fusion Antibodies plc                                  www.fusionantibodies.com (http://www.fusionantibodies.com/)
 Richard Jones, Chief Executive Officer                 Via Walbrook PR
 James Fair, Chief Financial Officer

 Allenby Capital Limited                                Tel: +44 (0)20 3328 5656
 James Reeve / Vivek Bhardwaj (Corporate Finance)
 Tony Quirke (Sales and Corporate Broking)

 Walbrook PR                Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
 Anna Dunphy                Mob: +44 (0)7876 741 001
 Paul McManus               Mob: +44 (0)7980 541 893

 

About Fusion Antibodies plc

 

Fusion is a Belfast-based Collaborative Research Organisation ("CRO") company,
listed on AIM, providing a range of antibody engineering services for the
development of antibodies for both therapeutic drug and diagnostic
applications.

 

Fusion provides a broad range of services in antibody generation, development,
characterisation, optimisation, and small-scale production. These services
include antigen expression, purification and sequencing, antibody humanisation
using Fusion's proprietary CDRx(TM) platform and cell line development,
producing antibody generating stable cell lines optimised for use downstream
by the customer to produce material for clinical trials. Since 2012, the
Company has successfully sequenced and expressed over 250 antibodies and
successfully completed over 200 humanisation projects for its international
customer base, which has included eight of the top 10 global pharmaceutical
companies by revenue.

 

At every stage, our client's vision is central to how we work in combining the
latest technological advances with cutting edge science. In this work our
world-class humanization and antibody optimization platforms harness the power
of natural somatic hypermutation (SHM) to ensure the best molecule goes to the
clinic. Fusion Antibodies' growth strategy is based on enabling Pharma and
Biotech companies get to the clinic more effectively, using molecules with
optimized therapeutic profile and enhanced potential for successful
development and approval and, ultimately, on speeding up the drug discovery
and development process. Fusion's use of SHM to create a fully human antibody
library to capture the human antibody repertoire will address a continuing
market need in antibody discovery,

 

Fusion Antibodies' emphasis on antibody therapeutics is based on the size and
growth rate in the sector, with the market valued at $135.4 billion in 2018
and forecast to surpass $300 billion by 2025, a CAGR of 14.26%. As of May
2021, there were 100 approved antibody therapies on the market and more than
570 antibody therapies in clinical development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRBLBDDCUBDGBX